Delivery Order SPE2DB20D2014-SPE2DB24FC26U

Award Date 6/18/24
Potential Completion Date 6/20/24
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp's Corporate Office Division a delivery order contract worth $1,094.44 for the supply of 4566110547 - Pimecrolimus 1% Cream 100 gm. The contract, which has a completion date of October 16, 2024, is a firm fixed-price award with no set-aside designation. Amerisourcebergen is a major pharmaceutical distributor that has been awarded numerous federal contracts to provide a wide range of essential medical products, including...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,681.13, is a delivery order for 4568038421 - Pimecrolimus 1% Cream 100GM. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 28, 2025. Amerisourcebergen Drug Corp is the prime contractor and has a significant Indefinite Delivery Contract (IDC) with...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,835.77 Delivery Order contract is for the supply of Pimecrolimus 1% Cream 30GM, a specialty pharmaceutical product, to support military healthcare programs. The contract has a completion date of January 29, 2025 and utilizes a Firm Fixed Price pricing type. This award is part of a larger $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,028.79 firm fixed-price delivery order is for the supply of Pimecrolimus 1% Cream 30gm, a pharmaceutical product, with a performance period ending on April 18, 2025. The contract is not set aside and is considered an open competition award. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,209.61 firm fixed-price delivery order is for the supply of Pimecrolimus 1% Cream 30GM, with a period of performance through January 28, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,013.34 firm fixed-price delivery order is for the supply of Pimecrolimus 1% Cream, a topical medication. The contract has an ultimate completion date of August 31, 2022. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,033.53 firm fixed-price delivery order is for the supply of Pimecrolimus 1% Cream, a topical medication. The award has an ultimate completion date of September 12, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Pimecrolimus 1% Cream in 100 gram quantities. The contract has a ceiling value of $1,077.13 and is a Firm Fixed Price Delivery Order issued by the Defense Logistics Agency, a defense agency. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the Defense Logistics Agency...
This federal contract award, valued at $2,494.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PIMECROLIMUS 1% CREAM 100GM, a pharmaceutical product, with a completion date of April 21, 2023. This contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,405.26, is for the supply of Pimecrolimus 1% Cream 30GM, a pharmaceutical product. The contract has an ultimate completion date of November 29, 2023 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB24FC26U
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, to provide Pimecrolimus 1% Cream 100GM to the government. The $2,628.01 firm-fixed-price delivery order has a completion date of June 20, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation, indicating it was awarded through full and open competition.

Generated 9/17/24, 9:49 AM